Clinical Trials Logo
  1. Home
  2. ER+ Breast Cancer
  3. NCT00828854

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

ER+ Breast Cancer Clinical Trial

Official title:
A Phase 2 Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Clinical Trial Summary

The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor. It is hypothesized that entinostat with continued AI will increase the estimated AI clinical benefit rate (CBR) from 5% to 25% with an acceptable safety profile.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00828854
Study type Interventional
Source Syndax Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date October 1, 2008
Completion date November 24, 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Completed NCT04312347 - Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels N/A
Recruiting NCT06064812 - A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. Phase 1
Completed NCT05423730 - Alcohol and Breast Cancer (ABC) Trial Early Phase 1
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05525481 - Tamoxifen Prediction Study in Patients With ER+ Breast Cancer Phase 4
Recruiting NCT04824014 - 4FMFES-PET Imaging of ER+ Advanced Breast Cancers Phase 2
Recruiting NCT06395519 - A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Phase 1
Recruiting NCT04985266 - A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer Phase 2
Completed NCT00676663 - Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer Phase 2
Active, not recruiting NCT04551495 - Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Phase 2
Recruiting NCT04920708 - Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression Phase 2
Not yet recruiting NCT06407401 - Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer Phase 3
Completed NCT01202591 - Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients Phase 1/Phase 2
Recruiting NCT05490472 - JAB-2485 Activity in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02580448 - CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Phase 1/Phase 2
Recruiting NCT04360941 - PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer Phase 1